Lysyl oxidase interactions with TGF-β during angiogenesis are mediated by endothelin 1

Hagar Grunwald[1], Kristina L.Hunker[2], Isabelle Birt[2], Rohtem Aviram[1], Shelly Zaffryar-Eilot [1], Santhi K. Ganesh[2] and Peleg Hasson[1]

1   Department of Genetics and Developmental Biology, The Rappaport Faculty of Medicine and Research Institute, Technion – Israel Institute of Technology, Haifa 31096, Israel

2   Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

3   Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA

* correspondence: phasson@technion.ac.il

Running title: LOX:TGFβ vascular interactions mediated via ET1

Lysyl oxidase

Vascular maturation

Abstract

Crosstalk between multiple components underlies formation of mature vessels. Although the players involved in angiogenesis have been identified, mechanisms underlying the crosstalk between them are still unclear. Using the ex-vivo aortic ring assay, we set out to dissect the interactions between two key angiogenic signaling pathways, vascular endothelial growth factor (VEGF) and transforming growth factor β (TGFβ), with members of the Lysyl oxidase family of matrix modifying enzymes. We find an interplay between VEGF, TGFβ, and the lysyl oxidases is essential for formation of mature vSMC-coated vessels. RNA sequencing analysis further identified an interaction with the endothelin-1 pathway. Our work implicates endothelin-1 downstream of TGFβ in vascular maturation and demonstrate the complexity of processes involved in generating vSMC coated vessels.

Non-standard abbreviations used in the manuscript:

Lox – Lysyl oxidase

βAPN – beta-aminopropionitrile

TGFβ – transforming growth factor beta

VEGF – vascular endothelial growth factor

ET1 – endothelin 1

ECM – extracellular matrix

EC – endothelial cells

vSMC – vascular smooth muscle cells

HUVEC - Human umbilical vascular endothelial cells

MOVAS – mouse vascular aorta cells

FDR – false discovery rate

Ednra/ETA – endothelin receptor type A

Ednrb/ETB – endothelin receptor type B

PDGFRβ - Platelet Derived Growth Factor Receptor beta

RNAseq – RNA sequencing

Introduction

Vascular development and maintenance of the arterial wall are complex processes. Signal mediated crosstalk between cell types and the extracellular matrix (ECM) are required to form layers that sheath the endothelial cells (EC) with vascular smooth muscle cells (vSMC) and an ECM scaffold of proteins, such as collagens and elastins, to provide structural integrity and elasticity to the artery. Abnormal interactions between these components can result in arterial weakness or fragility, manifested as arterial aneurysms or dissections. While many of the players involved in arterial development and maintenance have been identified, the mechanisms involved in the crosstalk between them are still unclear. Angiogenesis, the process of generating new vessels from a pre-existing one, can serve as a good model to study the mechanisms that underlie the interactions within the vasculature.

The angiogenic process begins with modulating a specific area of an existing vessel, created by extracellular (mostly paracrine) signals, most predominantly vascular endothelial growth factor A (VEGFA) (1). VEGF induces changes in EC characteristics from epithelial like into mesenchymal-like cells promoting their migration. The ECs lead the growing sprout through the ECM with the help of repulsive or adhesive molecules forming an endothelial sprout. In the following step, EC proliferation is reduced and recruitment of mural cells (pericytes and vSMC) takes place as part of the vessel's maturation (2). Both cell-types create direct cell-cell contact with the ECs. This maturation phase is mediated by several factors, including transforming growth factor β1 (TGFβ1), playing a major role (2).

The activity of paracrine signals such as VEGF and TGFβ has been shown to be affected by multiple extracellular factors (3, 4). A key family of secreted matrix modifying enzymes that have been previously demonstrated to modulate the activity of multiple signaling pathways including VEGF and TGFβ are the lysyl oxidases (LOXs) (5-8). This family of enzymes consists of five members including Lysyl oxidase (LOX) and LOX-Like (LOXL) 1-4 (8). LOX family members have been implicated in multiple processes including angiogenesis and vascular maintenance. The importance of LOX in arterial homeostasis has been demonstrated in humans and mice carrying mutations in the LOX gene. These individuals are susceptible to

thoracic aortic aneurysms and dissections (9-11). Mouse models of LOX inhibition using the pan-LOXs irreversible inhibitor beta-aminopropionitrile (βAPN) (12) demonstrate similar aortic pathologies further reinforcing the significant roles these enzymes play in the vasculature.

Complicating the dissection of LOX in vascular development and maintenance is the broad expression and somewhat overlapping activities of the other LOXL enzymes, where several members are expressed in ECs, vSMCs and in fibroblasts coating the large vessels (8). To gain insight into the interplay between key signaling pathways within the vasculature and examine whether LOX family members play a role in this crosstalk, we employed the ex-vivo aortic ring assay in which the distinct layers of the vessel are maintained, vascular sprouts form, mature and can be imaged yet all with the benefit of a cultured and controlled environment. Taking advantage of the aortic ring assay and RNA sequencing analyses from distinct treatments, we find novel roles for LOX family members in vascular maturation. We further identify a novel role for the vasoconstrictor protein endothelin-1 (ET1) in vascular maturation. Our results not only implicate the ET1 cascade in a novel process, but they also highlight another layer of complexity in the crosstalk between distinct cell types and interplay between signaling pathways, opening novel avenues for interventions.

Materials and Methods

Mice: C57BL/6 mice were obtained from Harlan Inc. All experiments involving live vertebrates conform to the relevant regulatory standards [Technion Institutional Care and Animal Use Committee (IACUC) and national animal welfare laws, guidelines, and policies].

Aortic ring assay: Aortic ring assay was performed essentially as previously described (13). Briefly, 6-week-old female mice were anesthetized with isoflurane and decapitated to avoid aortic damage caused by neck dislocation. Later, mice were disinfected with 70% ethanol before cut open. The rib cage was opened at the sides exposing the entire thoracic cavity. The aorta was gently cut loose from the spine using fine scissors and kept in cold Opti-MEM (Gibco) with 1% Penicillin Streptomycin. Following isolation, the aorta was thoroughly cleaned from fat and vascular branches. Next, under a dissecting microscope, it was cut into 0.5mm width rings. Following an overnight serum starvation, to equilibrate growth factor responses and create a uniform baseline state, the rings were embedded in collagen matrix and

fed with growth medium supplemented with the desired treatment (13). Prior to growth regression, rings were fixed (using 4% paraformaldehyde) and immunofluorescent staining was performed to examine sprout structure and coverage. For each experimental condition an average of 10 rings was carried out per experiment. Results demonstrated are summaries of at least 3 independent distinct experiments summarizing ~30 aortic rings. Quantification of immunostaining results is based on at least 5 representative rings from 3 independent experiments.

Migration assay: HUVECs were kindly contributed by Gera Neufeld's lab and MOVAS cells were contributed by Itzhak Kehat's lab. HUVEC or MOVAS were seeded at close to 100% confluence in an ImageLock™ 96-well plate and grown in a 37°C, 5% CO_2 incubator. The HUVEC were grown in M199 supplemented with 20% fetal calf serum (FCS), 1% penstrep, 1% Q and XF (5ng/ml). The MOVAS were grown in DMEM (Biological Industries) supplemented with 10% FCS, 1% pen-strep and 1% Q. After an overnight starvation (M199 supplemented with 10% FCS, 1% pen-strep and XF (5ng/ml) and serum-free DMEM supplemented with 1% pen-strep and 1% Q, respectively) the desired treatments were added. A scratch was done using a WoundMaker tool (Essen BioScience), a 96-pin mechanical device designed to create homogeneous scratch wounds per plate. Images were taken at a 30 minutes interval in the IncuCyte ZOOM® incubator.

Proliferation assays: SMCs- Vascular smooth muscle cells were counted manually (camera) and 20,000 cells were plated in a 12 multiwell plate dishes (Thermo scientific). Cells were kept in Opti-MEM medium (Gibco), 24hr and 48h post plating, and were then counted using Beckman Z1 coulter® particle counter. ECs- HUVEC were seeded on 24-multiwell plate coated with PBS-GEL at 10,000 cells/well in medium supplemented with 20% serum and allowed to attach for 4-5 h. Cells were changed to media with 10% serum supplemented with VEGF, VEGF+βAPN or VEGF+βAPN+TGF-β and Negative control (no treatment). Cells were allowed to proliferate for 48 h. Treatments were replaced on a daily basis. Cell number was determined by Beckman Z1 coulter® particle counter. Following similar treatments for 48 hours, cells were fixed and stained using anti-Ki67 to directly monitor proliferating cells. Relative proliferation was measured using the ratio between Ki67 expressing nuclei and number of cells.

Immunohistochemistry: Immunohistochemistry of aortic rings was performed essentially as previously described (13, 14). The following antibodies were used:

αSMA (1:100; Cell Marque), Ki67 (1:100; Cell Marque) and PECAM (1:50; Dianova).

Statistical Analyses: Statistical analyses were carried out using GraphPad software and T-test or 1-way Anova were used. Significance was considered as a minimum p value of <0.05.

RNAseq: RNA Sequencing was performed at the Biomedical Research Core Facilities at the University of Michigan. Libraries were prepared using the NEB Ultra Low RNA kit using 30ng of input RNA. The samples were sequenced 100bp paired end on Illumina HiSeq2000. The samples were run over 2 lanes, 12 samples per lane, and produced an average of around 50 million reads per sample. Quality control was performed using FastQC (v0.11.2) and overrepresented sequences (adapters) were removed using CUTADAPT tool (v 1.8).

Differential Expression: Reads were then aligned to mouse reference genome and annotation file (Mus_musculus.GRCm38.73 downloaded from ENSEMBL) using Bowtie2 (v2.2.9). The number of reads per gene was counted using summarizeOverlaps (v1.8.1) in R Studio. Differential expression analysis was performed using DESeq2 (version 1.12.0).

Pathway Analysis: Reads were aligned to mouse reference genome and annotation file (Mus_musculus.GRCm38.80 downloaded from ENSEMBL) using TopHat (v2.0.13) allowing two mismatches per read with options -very-sensitive and –transcriptome-index. The number of reads per gene was counted using Htseq (0.6.1). Differential expression analysis was performed using DESeq2 for further investigation of function and pathway enrichment using Ingenuity Pathway Analysis (IPA) (Bioinformatics 30:523-30).

Results:

Members of the Lysyl oxidase enzyme family are best known as key regulators of collagen and elastin crosslinking and as such play a critical role in vascular development and homeostasis (11, 15). However accumulating work has demonstrated that apart from their classical matrix crosslinking activities they also play a role in multiple aspects of cell behavior by regulating signaling pathways (5, 16).

To dissect lysyl oxidases' vascular activities and their interactions with signaling pathways in a controlled environment, yet in a way that will maintain the general

structure of the vasculature with its distinct layers, we employed the aortic ring assay (13). Briefly, aortas were dissected from the mice, cleaned and cut into thin (0.5mm) rings. Following overnight serum starvation to equilibrate their growth factor responses and create a uniform baseline state, the rings were embedded in collagen matrix and fed with growth medium supplemented with the desired treatment (13). To address the roles of the lysyl oxidases in vascular development we compared aortic rings that were supplemented with 30ng/ml VEGF versus ones that were treated with a similar dose of VEGF yet in which the lysyl oxidases' enzymatic activities were inhibited. As multiple lysyl oxidases are expressed in the distinct aortic layers (Supp. Table 1), to block their activities we took advantage of βAPN, an irreversible wide-range inhibitor of all lysyl oxidases enzymatic activities (12) (Supp. Fig. 1A). Treatment of the aortic rings with βAPN only did not result in any change and these were similar to those that have received no treatment (Fig. 1A).

Angiogenic sprouts from the aortic rings were observed already two days after incubation with VEGF. By the third day multiple branched sprouts were visible. These sprouts continued to grow and split, until reaching a peak point, as long as VEGF remained in the growth media (Figure 1C). Immunostaining for CD31/PECAM marking ECs and αsmooth muscle actin (αSMA) marking vSMCs demonstrates that 98% of the angiogenic sprouts (n=111 sprouts) have matured and were coated with vSMCs (Fig. 1B-D'). In striking contrast, following the βAPN-mediated inhibition of LOX family enzymatic activities, angiogenesis was dramatically inhibited and sprouts did not emerge even though VEGF was present in the media (Fig. 1E; n=30 rings). Notably, although multiple vSMCs emigrated from the aortic ring, no endothelial sprouts have formed in the VEGF+βAPN treated rings (Fig. 1F,F').

We next wished to test whether βAPN treatment also affects the already mature vSMC coated sprouts. Towards that end, aortic rings were embedded in a collagen matrix as above and supplemented with VEGF for the duration of one week (Supp. Fig. 1B). By the end of the week highly branched vSMC coated sprouts have formed. In the following week, the rings were maintained in VEGF supplemented media or in VEGF+βAPN media for an additional week followed by immunostaining analysis (Supp. Fig. 1B). We find that the endothelial sprouts were mostly maintained in both treatment groups (Supp. Fig. 1C,D) although those cultured in the presence of βAPN were not as organized as those treated with VEGF alone. Notably, although vSMCs

were abundant in the matrix, the coverage of the sprouts was severely compromised in the VEGF+βAPN treatment group where endothelial sprouts lost their vSMC coverage and vSMCs seemed disorganized (Supp. Fig. 1E,F"). These results raise the possibility that blocking LOXs' enzymatic activity affected the interactions between the vSMC and the underlying endothelial cells.

To test what could mediate the crosstalk between the two cell types we searched for a signal that has been implicated in 1) angiogenesis in endothelial cells, 2) vSMC-dependent processes and 3) that is known to interact with lysyl oxidases. One such candidate fulfilling the above criteria is the TGFβ pathway. To confirm previous observations and test whether the aortic ring assay could also be used in monitoring TGFβ angiogenic properties, we treated aortic rings with TGFβ1. While no sprouts form in the non-treated rings and numerous vSMC-coated sprouts form in the VEGF-treated rings, we find that following this treatment multiple endothelial sprouts form and that 50% of them (n=99 sprouts) were coated with vSMC (Fig. 2A-C'''). This activity is completely blocked by the addition of a TGFβ Receptor 1 (TGFβR1) kinase inhibitor (Supp. Fig. 2A,B) demonstrating the specificity of the treatment.

To test whether the inhibition of lysyl oxidases enzymatic activity attenuates TGFβ angiogenic activities we cultured the aortic rings with recombinant TGFβ1 and βAPN. We find that although the inhibition was not as robust as observed in the VEGF+βAPN treated rings, a marked reduction in the number of endothelial sprouts that sprouted from the rings as well as in the vSMC coated sprouts was observed although significant vSMCs were spread within the collagen matrix (Fig. 2D-D''').

The observation that both VEGF and TGFβ1 could induce endothelial sprouts that are coated with vSMCs and that both these signals are affected by LOX inhibition (although to different levels), raised the possibility TGFβ1 signaling is acting downstream of VEGF, the main angiogenic pathway. To test whether this is the case, we treated aortic rings with VEGF and the TGFβR1 kinase inhibitor and monitored sprout formation. vSMC coated endothelial sprouts have still formed following this treatment demonstrating that TGFβ1 does not act downstream of VEGF in this assay (Supp. Fig. 2C-D").

Having verified the independent requirement of both signaling pathways and their dependence on lysyl oxidases' activity we wished to test whether activation of both cascades could rescue the βAPN-mediated angiogenic inhibition. Towards that end, following their embedding, the aortic rings were treated with media containing all

three factors, VEGF, TGFβ1 and βAPN. Notably, we find that multiple endothelial sprouts form and 70% of these (n=147 sprouts) are coated with vSMCs (Fig. 2E-E'''). These results suggest that an interplay between the two pathways could, to a large extent, bypass the dependence on lysyl oxidases activity facilitating the formation of mature vSMC coated endothelial sprouts.

The observation that activation of the two pathways was able to rescue the βAPN mediated angiogenic inhibition could be caused by the cascades' activity on one cell type or on the crosstalk between them. vSMC coating of endothelial sprouts involves multiple processes including cell proliferation, migration, adhesion and organization (e.g., tube/cord formation). Any of these processes could, in principle, be affected by βAPN. To distinguish between these possibilities, we set to treat each cell type independently and monitor the response to the distinct treatments.

Human umbilical vascular endothelial cells (HUVEC) migrate and form cords when grown on matrigel. We thus tested the effects of βAPN and TGFβ1/VEGF on HUVEC migration, proliferation and cord formation. We find neither lysyl oxidases' enzymatic inhibition nor does TGFβ supplementation affect HUVEC migration (Fig. 3A-E) or cell proliferation (Fig. 3 F-G and Supp. Fig. 3). Likewise these treatments had no effect on HUVECs cord formation capabilities (Fig. 3H-M).

That βAPN did not affect EC behavior (migration, proliferation and cord formation) raised the possibility that the dramatic angiogenic inhibition observed in the aortic ring assay might be carried out primarily on the vSMCs. Using MOVAS cells, a vSMC line derived from mouse aorta, we set to test whether βAPN and TGFβ affected vSMC behavior. We thus monitored their proliferation, adhesion, and migration, critical properties required for coating the nascent sprouts. In a similar manner to the observed lack of effect on HUVEC, we did not detect major changes in these properties following βAPN or TGFβ administration to the vSMC media (Fig. 4 and Supp. Fig. 4). Altogether, the above results reinforce the notion that the effects mediated by βAPN on the sprouts which are rescued by TGFβ1 are not due to the specific lysyl oxidases inhibition in one cell type but possibly on the interplay between them.

To identify how TGFβ1 overcomes the angiogenic inhibition mediated by βAPN, we carried out a RNAseq analysis from aortic rings derived from the following four conditions: 1) no treatment (rings were grown in DMEM only) 2) VEGF; 3) VEGF+βAPN and 4) VEGF+βAPN+TGFβ1. Briefly, the aortic rings were incubated

for 3 days with the distinct media (as in Figs. 1,2) and then RNA was extracted for further analysis. We then ran two group comparisons using the DESeq package in R studio (17) to observe differentially expressed genes within each condition in an unbiased manner. Wald significance tests were run between the untreated and treated groups for each of the three conditions and p-values were corrected using the Benjamini–Hochberg procedure. The largest treatment effect was observed in the VEGF+ βAPN+TGFβ1, with 1,787 differentially expressed genes (FDR<0.1). The effect of VEGF alone was significant for 393 genes, while the effect of VEGF+ βAPN was only slightly larger with 552 genes showing differential expression (FDR<0.1).

Among the top five genes in both the VEGF and VEGF+βAPN differentially expressed gene lists was endothelin receptor type B (Ednrb/ETB) (Fig. 5, Supp. Table 2). Likewise, we found that endothelin receptor type A (Ednra/ETA) showed significantly higher expression in the VEGF treatment group (Fig. 5). To observe whether this effect on Ednrb/ETB persisted after the addition of TGFβ1, we queried all endothelin genes in the VEGF+βAPN+TGFβ1 versus untreated results. The endothelin receptors were found to have similar expression to the untreated group, however the endothelin 1 (Edn1) gene itself showed significantly higher expression with VEGF+βAPN+TGFβ1 treatment (Fig. 5). For a complete picture of the different effects between each condition, we also ran two group comparisons between each treatment group. Notably, only one gene showed differential expression between the VEGF and VEGF+βAPN conditions at FDR < 0.1 (Supp. Table 2).

Should the endothelin cascade be at the core of the crosstalk unveiled by the TGFβ dependent rescue of the vascular sprouts then activating it also in the presence of βAPN but without supplementing TGFβ1 should induce vascular sprouts. However, activation of the endothelin cascade can also induce TGFβ itself (18), raising the possibility that such an exogenous induction of the pathway will induce TGFβ which in turn will promote vascular sprouts. To test whether this is the case, or whether recombinant ET-1 (rET-1) can induce sprout formation independently of TGFβ signaling we set to block the latter and assess whether vascular sprouts still form upon rET-1 administration. As a negative control, to test the validity of the inhibition regime, we first cultured the aortic rings in VEGF+βAPN+TGFβ+TGFβR1 inhibitor. As expected, no sprouts form upon this combined treatment and they resembled those cultured in VEGF+βAPN (Fig. 6A-C cf. Fig. 1E-F').

Treatment of aortic rings only with rET-1 does not induce vascular sprouts, resembling the negative control rings (Supp. Fig. 5). In contrast, the addition of rET-1 together with VEGF and βAPN promotes mature vSMC coated sprouts (Fig. 6D-D"; 21 out of 21 sprouts). To directly test whether this induction is due to ET-1's induction of the TGFβ cascade, we further supplemented the aortic rings' growth media also with a TGFβR1 inhibitor. We find that even upon the inhibition of the TGFβ cascade, vSMC coated sprouts form (Fig. 6E-E"). Altogether, these results may suggest that the activation of the endothelin pathway is acting downstream of TGFβ signaling and able to induce angiogenesis in concert with VEGF and mediate vSMC coating of nascent endothelial vessels.

Discussion

Angiogenic growth is a well-balanced orchestra of events. Proper vessel growth requires synchronization and regulation of multiple events such as endothelial emergence out of the original vessel's wall, proliferation, migration, adhesion and finally recruitment of vSMC as part of the maturation process. Although many studies have explored these events thoroughly, our understanding is still incomplete. In this work we demonstrated a new interplay between key regulators of the angiogenic process, VEGF and TGFβ1 and the lysyl oxidase family of enzymes during angiogenesis. We demonstrate the involvement of an additional player, Endothelin-1, as part of the interplay between these factors in this process.

Vascular deformities in lathyric animals (19, 20) knockout in mice (8, 11, 21) and mutations in humans (9, 10, 22) demonstrated the lysyl oxidases are indispensable enzymes during vessel growth and maintenance. While much focus has been given to their role in the ECM, this activity is usually a matter of a relatively prolonged period of time, even when explored in *in-vitro* studies (23, 24). Here we show, that following a short period of time (3-4 days), a significant phenotype is already observed following these enzymes' inhibition, where regardless of VEGF, vascular sprouting was rapidly inhibited suggesting it may be an ECM unrelated process. Along these lines, accumulating evidence demonstrates that members of the family entail multiple ECM-independent activities. One such example is the oxidation of Platelet Derived Growth Factor Receptor β (PDGFRβ) resulting in *VEGF* mRNA upregulation (5). Our RNAseq analyses demonstrated that in the βAPN+VEGF treated aortas only few genes' expression was significantly changed in comparison to those treated with

VEGF alone therefore suggesting that βAPN did not inhibit the cascade but rather a downstream process. Thus, the observations that lysyl oxidases inhibition was sufficient to inhibit VEGF mediated angiogenesis demonstrates these enzymes can also act downstream of VEGF (Fig. 1) establishes a new, as yet undemonstrated role for lysyl oxidases in regulating vessel growth.

We and others find intertwined interactions between LOX and TGFβ in multiple settings. As a leading contributor to ECM organization, LOX is indirectly responsible for the maintenance of latent TGFβ bound to ECM components. Furthermore, LOX was shown to physically bind TGFβ1 in an enzymatic-independent manner and attenuate its signaling capacity via TGFβ1 oxidation (25). We have previously demonstrated the interactions between the two also in embryonic muscle development where augmented TGFβ signaling was observed in *Lox* mutant embryos and many of the mutant-associated muscle phenotypes could be rescued by TGFβ inhibition (6). Interestingly however, when the *Lox* mutant "TGFβ-inhibited" embryos were harvested, numerous hemorrhages were observed at earlier stages and in larger quantities than normally observed in these mutant embryos (6). These observations suggested that TGFβ signaling might have a protective role in angiogenesis in situations where Lox is missing. Correspondingly, our aortic ring results further reinforce opposite effects of TGFβ1 and LOX (Fig. 2). That TGFβ1 rescued the vessels even in the presence of βAPN and that blocking its activity did not affect VEGF signaling, place TGFβ1 downstream to Lox and in parallel to VEGF signaling (Fig. 6).

The observation that βAPN treatment had an effect on vSMC coating of the endothelial sprouts in the aortic ring assay but not when administered to the single cell types suggested LOX inhibition affects a crosstalk between ECs and vSMCs. To identify the underlying players, RNAseq analysis was carried out monitoring gene expression changes in the distinct treatments. Surprisingly expression of only a few genes was significantly altered between the VEGF vs. VEGF+βAPN treatments, suggesting the VEGF pathway was not blocked in the βAPN treatment. Along these lines, no effect on cell death was observed suggesting the lack of vascular sprouts was not a result of this process. To facilitate identifying the process at the heart of the phenotypes we searched for an 'on-off-on' or 'off-on-off' behavior, representing the aortic ring assay phenotypes; VEGF-induced growth, βAPN-mediated inhibition and TGFβ1mediated rescue. The Endothelin-1 pathway was one such candidate; VEGF

induced expression of the ETA and ETB receptors expressed on ECs and vSMCs while TGFβ induced expression of the ligand, ET-1.

Our RNAseq results indicate an association between the ET-1 cascade and the 'on-off-on' phenotype detected in the aortic ring assay. In our assays both VEGF and TGFβ1 led to vessel growth, while βAPN-mediated inhibition, drove vessel restriction and inhibited maturation (Figs 1,2). Interestingly, in both VEGF and TGFβ1 treatments, where vessel growth prospers, the resulting effect is an activation of the ET-1 pathway, via receptor's upregulation in the VEGF treatment or ligand upregulation in the TGFβ1 treatment (Fig. 5). The interplay between TGFβ1 and ET-1 is well documented in the literature. TGFβ1 was shown to induce ET-1 expression in human dermal fibroblasts (18), matching our RNAseq results where TGFβ1 upregulated ET-1 expression in EC. Moreover, several studies explored TGFβ1 fibrotic effect through the induction of profibrotic gene expression and found it to be ET-1-dependent (18, 26). Thus, it remains possible that TGFβ1-mediated angiogenesis rescue is also ET-1-dependent. Using Bosentan, an antagonist of ET-1 able to bind both ETA and ETB, we aimed to address this question however we were not successful as its administration led to a complete arrest of cell emigration (data not shown) suggesting the aortic ring assay may not be a suitable assay for addressing its functions. Further experiments beyond the scope of this work are required to test whether ET-1 is indispensable for the TGFβ1-mediated recovery of growth.

Overall, our results highlight an as yet unexplored role of ET-1 in angiogenesis – vascular maturation. Using the aortic ring assay, we were able to uncover an interaction between the lysyl oxidases and the Endothelin pathway that is mediated by TGFβ. Both LOX and ET-1 are known to play key roles in angiogenesis and they both have well documented influence on ECM, fibrosis and cancer. Thus, further dissection of their interactions can yield possible new treatment modalities to affect angiogenic pathways.

cell culture and Lox activity assays. P.H planned the study, supervised and analyzed the data. SKG and PH wrote the manuscript.

References

1. Apte, R. S., Chen, D. S., and Ferrara, N. (2019) VEGF in Signaling and Disease: Beyond Discovery and Development. *Cell* **176**, 1248-1264

2. Jain, R. K. (2003) Molecular regulation of vessel maturation. *Nat Med* **9**, 685-693

3. Adams, R. H., and Alitalo, K. (2007) Molecular regulation of angiogenesis and lymphangiogenesis. *Nature reviews. Molecular cell biology* **8**, 464-478

4. ten Dijke, P., and Arthur, H. M. (2007) Extracellular control of TGFbeta signalling in vascular development and disease. *Nature reviews. Molecular cell biology* **8**, 857-869

5. Baker, A. M., Bird, D., Welti, J. C., Gourlaouen, M., Lang, G., Murray, G. I., Reynolds, A. R., Cox, T. R., and Erler, J. T. (2013) Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. *Cancer research* **73**, 583-594

6. Kutchuk, L., Laitala, A., Soueid-Bomgarten, S., Shentzer, P., Rosendahl, A. H., Eilot, S., Grossman, M., Sagi, I., Sormunen, R., Myllyharju, J., Maki, J. M., and Hasson, P. (2015) Muscle composition is regulated by a Lox-TGFbeta feedback loop. *Development (Cambridge, England)* **142**, 983-993

7. Lucero, H. A., Ravid, K., Grimsby, J. L., Rich, C. B., DiCamillo, S. J., Mäki, J. M., Myllyharju, J., and Kagan, H. M. (2008) Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells. *The Journal of biological chemistry* **283**, 24103-24117

8. Mäki, J. M. (2009) Lysyl oxidases in mammalian development and certain pathological conditions. *Histology and histopathology* **24**, 651-660

9. Guo, D. C., Regalado, E. S., Gong, L., Duan, X., Santos-Cortez, R. L., Arnaud, P., Ren, Z., Cai, B., Hostetler, E. M., Moran, R., Liang, D., Estrera, A., Safi, H. J., Leal, S. M., Bamshad, M. J., Shendure, J., Nickerson, D. A., Jondeau, G., Boileau, C., and Milewicz, D. M. (2016) LOX Mutations Predispose to Thoracic Aortic Aneurysms and Dissections. *Circulation*

research **118**, 928-934

10. Lee, V. S., Halabi, C. M., Hoffman, E. P., Carmichael, N., Leshchiner, I., Lian, C. G., Bierhals, A. J., Vuzman, D., Mecham, R. P., Frank, N. Y., and Stitziel, N. O. (2016) Loss of function mutation in LOX causes thoracic aortic aneurysm and dissection in humans. *Proceedings of the National Academy of Sciences of the United States of America* **113**, 8759-8764

11. Mäki, J. M., Rasanen, J., Tikkanen, H., Sormunen, R., Makikallio, K., Kivirikko, K. I., and Soininen, R. (2002) Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. *Circulation* **106**, 2503-2509

12. Narayanan, A. S., Siegel, R. C., and Martin, G. R. (1972) On the inhibition of lysyl oxidase by -aminopropionitrile. *Biochemical and biophysical research communications* **46**, 745751

13. Baker, M., Robinson, S. D., Lechertier, T., Barber, P. R., Tavora, B., D'Amico, G., Jones, D. T., Vojnovic, B., and Hodivala-Dilke, K. (2011) Use of the mouse aortic ring assay to study angiogenesis. *Nature protocols* **7**, 89-104

14. Kraft-Sheleg, O., Zaffryar-Eilot, S., Genin, O., Yaseen, W., Soueid-Baumgarten, S., Kessler,
O., Smolkin, T., Akiri, G., Neufeld, G., Cinnamon, Y., and Hasson, P. (2016) Localized LoxL3Dependent Fibronectin Oxidation Regulates Myofiber Stretch and Integrin-Mediated Adhesion. *Developmental cell* **36**, 550-561

15. Mäki, J. M., Sormunen, R., Lippo, S., Kaarteenaho-Wiik, R., Soininen, R., and Myllyharju, J. (2005) Lysyl oxidase is essential for normal development and function of the respiratory system and for the integrity of elastic and collagen fibers in various tissues. *The American journal of pathology* **167**, 927-936

16. Gabay Yehezkely, R., Zaffryar-Eilot, S., Kaganovsky, A., Fainshtain Malka, N., Aviram, R., Livneh, I., and Hasson, P. (2020) Intracellular role for the matrix modifying enzyme Lox in regulating transcription factor subcellular localization and activity in muscle regeneration. *Developmental cell*

17. Love, M. I., Huber, W., and Anders, S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome biology* **15**, 550

18. Lagares, D., Garcia-Fernandez, R. A., Jimenez, C. L., Magan-Marchal, N., Busnadiego, O., Lamas, S., and Rodriguez-Pascual, F. (2010) Endothelin 1 contributes to the effect of transforming growth factor beta1 on wound repair and

skin fibrosis. *Arthritis Rheum* **62**, 878-889

19.   Mc, K. G., Lalich, J. J., Schilling, E. D., and Strong, F. M. (1954) A crystalline "lathyrus factor" from Lathyrus odoratus. *Arch Biochem Biophys* **52**, 313-322

20.   Pinnell, S. R., and Martin, G. R. (1968) The cross-linking of collagen and elastin: enzymatic conversion of lysine in peptide linkage to alpha-aminoadipic-delta-semialdehyde (allysine) by an extract from bone. *Proceedings of the National Academy of Sciences of the United States of America* **61**, 708-716

21.   Hornstra, I. K., Birge, S., Starcher, B., Bailey, A. J., Mecham, R. P., and Shapiro, S. D. (2003) Lysyl oxidase is required for vascular and diaphragmatic development in mice. *The Journal of biological chemistry* **278**, 14387-14393

22.   Lee, V. S., Halabi, C. M., Broekelmann, T. J., Trackman, P. C., Stitziel, N. O., and Mecham, R. P. (2019) Intracellular retention of mutant lysyl oxidase leads to aortic dilation in response to increased hemodynamic stress. *JCI insight* **5**

23.   Hong, H. H., Pischon, N., Santana, R. B., Palamakumbura, A. H., Chase, H. B., Gantz, D., Guo, Y., Uzel, M. I., Ma, D., and Trackman, P. C. (2004) A role for lysyl oxidase regulation in the control of normal collagen deposition in differentiating osteoblast cultures. *J Cell Physiol* **200**, 53-62

24.   Lei, Y., Masjedi, S., and Ferdous, Z. (2017) A study of extracellular matrix remodeling in aortic heart valves using a novel biaxial stretch bioreactor. *Journal of the mechanical behavior of biomedical materials* **75**, 351-358

25.   Atsawasuwan, P., Mochida, Y., Katafuchi, M., Kaku, M., Fong, K. S., Csiszar, K., and Yamauchi, M. (2008) Lysyl oxidase binds transforming growth factor-beta and regulates its signaling via amine oxidase activity. *The Journal of biological chemistry* **283**, 3422934240

26.   Wermuth, P. J., Li, Z., Mendoza, F. A., and Jimenez, S. A. (2016) Stimulation of Transforming Growth Factor-beta1-Induced Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1. *PloS one* **11**, e0161988

Figure legends

Figure 1. βAPN blocks vascular growth. Brightfield and fluorescent immunostaining of aortic rings treated with full medium (A,B,B'), VEGF (C,D,D') and VEGF+βAPN (E,F,F'). In B, D and F ECs are marked by CD31/PECAM (red) and vSMCs by αSMA (green). White arrows (B,F) mark vSMCs that have emigrated from the rings yet are not coating nascent endothelial vessels. White arrowhead in marks endothelial sprout (red, D,D') coated with vSMCs (green, D).

Figure 2. TGFβ1 rescues βAPN- mediated inhibition of vessel growth. Immunofluorescent images of aortic rings stained for CD31/PECAM marking ECs (red) and αSMA marking vSMC (green). Treatments are as indicated no treatment (A,-A'''); VEGF (B-B'''); TGFβ (C-C'''); TGFβ+βAPN (D-D''') and VEGF+TGFβ+βAPN (E-E'''). Note that although endothelial vessels form following βAPN and TGFβ treatment (D-D'') vSMCs (D''') are disorganized and do not coat the sprouts. In contrast, upon treating the rings with VEGF+TGFβ+βAPN (E-E''') vessels are properly coated by the vSMCs.

Figure 3. βAPN and TGFβ do not affect endothelial migration, proliferation or tube formation. Time course images of HUVECs treated as indicated with the gap lacking cells marked in red (A-D''). Quantification of 'wound' density in the distinct treatments (E). Quantification of HUVEC proliferation (F) and Ki67 immunostaining (G) with the distinct treatments. Images of HUVEC in a cord formation assay with the distinct treatments as indicated (H-K). Quantification of number of junctions (L) and total mesh area (M) demonstrate no significant difference is observed following the distinct treatments.

Figure 4. βAPN and TGFβ do not affect vSMC migration or proliferation. Time course images of MOVAS treated as indicated with the gap lacking cells marked in

green (A-D''). Quantification of 'wound' density in the distinct treatments (E). Proliferation assay (F) and Ki67 immunostaining (G) of MOVAS cells treated as mentioned demonstrate no difference following the distinct treatments.

Figure 5. Endothelin 1 related gene expression is affected by VEGF, TGFβ and Lox inhibition. Expression of Edn1, Ednra and Ednrb following the distinct treatments (A, B).

Figure 6. ET-1 rescues βAPN-mediated angiogenic inhibition. Immunostaining of aortic rings treated as indicated. Note that although TGFβ R1 inhibitor blocks VEGF mediated angiogenic rescue, it does not affect ET-1 rescue demonstrating ET-1 acts downstream of TGFβ1. Endothelial sprouts are marked by CD31/PECAM staining (red) while vSMC are stained with αSMA (green). White arrowheads (B,C) point to vSMC that have emigrated, demonstrating ring viability, although no sprouts are generated.

|	No treatment	VEGF	VEGF+βAPN

Figure 1

fsb2_21824_f1.tif

Figure 2

fsb2_21824_f2.tif

Figure 3

fsb2_21824_f3.tif

Figure 4

fsb2_21824_f4.tif

A.

| Gene	Fold Change			Q-value		
	VEGF	VEGF+βAPN	VEGF+βAPN+TGFβ1	VEGF	VEGF+βAPN	VEGF+βAPN+TGFβ1
Edn1	ns	ns	4.55	ns	ns	8.01E-03
Ednrb	4.16	4.67	ns	1.26E-08	1.39E-10	ns
Ednra	2.33	ns	ns	1.46E-02	ns	ns

B.

Figure 5

fsb2_21824_f5.tif

Figure 6

fsb2_21824_f6.tif